【摘要】 目的:观察低分子肝素联合化疗对晚期乳腺癌的疗效及对血栓标志物(D二聚体、纤维蛋白原)的影响。方法:42例晚期乳腺癌患者随机分成两组。A组:TP化疗组,应用紫杉醇135mg/m2第1天静脉滴注,顺铂70 mg/m2第2天静脉滴注。B组:低分子肝素联合TP方案化疗组,在A组用药的基础上加用低分子肝素5000U皮下注射12小时1次,共用5天。结果:低分子肝素组D二聚体化疗前后无明显变化(P>0.05),纤维蛋白原化疗后明显低于化疗前水平(P<0.05)。近期疗效肝素组(52.4%)高于对照组(42.8%),但统计学差异无显著性(P>0.05)。低分子肝素组治疗的不良反应较单纯化疗组统计学差异无显著性(P>0.05)。结论:应用低分子肝素联合化疗能改善晚期乳腺癌高凝状态,无明显不良反应。更多还原

【Abstract】 Objective:To observe the effect of low molecular heparin in combined with chemotherapy on blood clots markers D dimmers and fibrinogen in advanced breast cancer.Methods: Total of 42 patients with metastatic breast cancer were randomly divided into two groups,patients in group A received paclitaxel plus cisplatin;patients in group B received regimen TP combined with low molecular heparin 5000U subcutaneously injected q12 hours per day,for 5 days.Group B: low molecular heparin and TP scheme chemotherapy group,on the base of drug in group A combined with low molecular heparin 5000U subcutaneous injection 12 hours 1 times,for five days.Results: There was no significant difference in low molecular heparin group D-dimers before and after chemotherapy.Level of fibrinogen after chemotherapy was significantly lower than the level before chemotherapy(P<0.05).There was no significant difference in adverse effect between the two groups(P> 0.05).There was on significant differences in adverse reactions between 2 groups.Conclusion: The application of low molecular heparin combined chemotherapy can improve high pour-point state in advanced breast cancer without obvious adverse reactions.更多还原